Nepidermin
Nepidermin (brand name Easyef), also known as recombinant human epidermal growth factor (rhEGF), is a recombinant form of human epidermal growth factor (EGF) and a cicatrizant (a drug that promotes wound healing through formation of scar tissue). It was developed by Daewoong Pharmaceutical.[1][2][3] As a recombinant form of EGF, nepidermin is an agonist of the epidermal growth factor receptor (EGFR), and is the first EGFR agonist to be marketed.[2][3]
| Clinical data | |
|---|---|
| Trade names | Easyef, Genesoft, Kang He Su, Regen-D[1] |
| Other names | Recombinant human epidermal growth factor; rhEGF; DWP-401 |
| Routes of administration | Topical |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.241.060  |
| Chemical and physical data | |
| Formula | C270H401N73O83S7 |
| Molar mass | 6222.03 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is marketed as an ointment for the treatment of diabetic foot ulcers, wounds, and alopecia (hair loss) in Vietnam, the Philippines, Thailand, and China.[1][2][3]
As of 2017 it was in clinical trials in South Korea for the treatment of stomatitis (inflammation of the mouth or lips) and for reversal of skin side effects caused by erlotinib (an EGFR inhibitor).[2][4]
See also
References
- "Nepidermin". Drugs.com. Retrieved 3 June 2017.
- "Nepidermin". AdisInsight. Retrieved 3 June 2017.
- Lau, Hui-Chong; Kim, Aeri (2016). "Pharmaceutical perspectives of impaired wound healing in diabetic foot ulcer". Journal of Pharmaceutical Investigation. 46 (5): 403–423. doi:10.1007/s40005-016-0268-6. ISSN 2093-5552.
- Yuan A, Sonis S (2014). "Emerging therapies for the prevention and treatment of oral mucositis". Expert Opin Emerg Drugs. 19 (3): 343–51. doi:10.1517/14728214.2014.946403. PMID 25102771.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.